Chronic Myeloid Leukemia
📧 Sign up to get email alerts when something new happens for Chronic Myeloid Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2018-07-20Clinical Trial Update: Chronic Myelod Leukemia Registry at Asan Medical Center
The Chronic Myeloid Leukemia Registry at Asan Medical Center has been terminated. The registry covers chronic myeloid leukemia in chronic ph…
-
CLINICAL_TRIALS trial_result · 2018-07-05Clinical Trial Update: Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation [Phase 1]
Phase 1 trial update reporting completion of a study evaluating ultra-low-dose interleukin-2 as graft-versus-host disease prophylaxis in hap…
-
CLINICAL_TRIALS research · 2018-07-02Clinical Trial Update: Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer [NA]
Clinical trial update on caregiver-delivered massage therapy to improve quality of life in pediatric cancer patients; the study (NCT01053494…
-
CLINICAL_TRIALS research · 2018-06-29Clinical Trial Update: Persistence of MR3 in Chronic Myeloid Leukemia (CML) After a 2nd Stop of TKI Treatment [Phase 2]
Phase 2 clinical trial update investigating persistence of MR3 in relapsed chronic myeloid leukemia after a second stop of TKI therapy. The …
-
CLINICAL_TRIALS trial_result · 2018-06-15Clinical Trial Update: A Study to Evaluate Efficacy and Safety of Glinib in Newly Diagnosed CML Patients [Phase 4]
A Phase 4 study evaluating Glinib in newly diagnosed chronic myeloid leukemia patients has been terminated. The trial aimed to assess effica…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2018-06-11Clinical Trial Update: Cessation of Tyrosine Kinase Inhibitors in Patients With Chronic-phase Chronic Myelogenous Leukaemia
This document provides an update on a clinical trial evaluating cessation of tyrosine kinase inhibitor therapy in patients with chronic-phas…
-
CLINICAL_TRIALS research · 2018-06-08Clinical Trial Update: Preparatory Work to Assess Adherence to Oral Chemotherapy
A clinical trial update describing preparatory work to assess patient adherence to oral chemotherapy in Chronic Myeloid Leukemia.
-
CLINICAL_TRIALS trial_result · 2018-06-06Clinical Trial Update: Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell Transplantation
The National Cancer Institute-sponsored clinical trial assessing relapse in malignant blood cancers after allogeneic hematopoietic stem cell…
-
CLINICAL_TRIALS trial_result · 2018-06-04Clinical Trial Update: Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders [Phase 1, Phase 2]
The document notes the completion of a Phase 1/2 clinical trial evaluating tipifarnib in patients with chronic myeloid leukemia, chronic mye…
-
FDA approval · 2018-05-29FDA Approved: ICLUSIG — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
The FDA approved a supplemental application for ICLUSIG (ponatinib hydrochloride) filed by Takeda Pharmaceuticals America, Inc., marking a r…
-
CLINICAL_TRIALS trial_result · 2018-05-22Clinical Trial Update: Evaluation of the Therapeutic Effect of HU Pulse Therapy for CML Patients [Phase 3]
A Phase 3 clinical trial evaluating hydroxyurea pulse therapy for chronic myeloid leukemia; this update provides current status of the study…
-
CLINICAL_TRIALS trial_result · 2018-05-21Clinical Trial Update: Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients. [Phase 2]
Phase II open-label study assessing oral nilotinib in pediatric patients with Philadelphia chromosome–positive chronic myeloid leukemia; stu…
-
CLINICAL_TRIALS trial_result · 2018-05-16Clinical Trial Update: Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies [Phase 1]
This update describes safety data from a Phase 1 study of AP24534 (ponatinib) in patients with chronic myeloid leukemia and other hematologi…
-
CLINICAL_TRIALS trial_result · 2018-05-03Clinical Trial Update: Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia [Phase 3]
Phase 3 trial evaluating Imatinib Mesylate with or without Interferon Alfa or Cytarabine versus Interferon Alfa followed by donor stem cell …
-
CLINICAL_TRIALS trial_result · 2018-04-25Clinical Trial Update: Phase III Study of Compound Formula Realgar-Indigo Naturalis Plus Imatinib Versus Placebo Plus Imatinib in Adult CML-CP Patients With Ph+ [Phase 3]
A Phase 3 trial comparing Realgar-Indigo Naturalis plus Imatinib to placebo plus Imatinib in adults with Philadelphia chromosome-positive ch…
-
CLINICAL_TRIALS trial_result · 2018-04-24Clinical Trial Update: Comparison of Imatinib Versus Dasatinib in Patients With Newly-diagnosed Chronic Phase Chronic Myeloid Leukaemia [Phase 3]
A Phase 3 trial comparing imatinib to dasatinib in newly diagnosed chronic phase chronic myeloid leukemia has completed. The update provides…
-
CLINICAL_TRIALS trial_result · 2018-04-10Clinical Trial Update: Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies [Phase 2]
A Phase 2 trial evaluated haplotype-mismatched hematopoietic stem cell transplantation in patients with hematological malignancies. The stud…
-
FDA label_change · 2018-03-22FDA Approved: TASIGNA — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for TASIGNA (nilotinib) from Novartis to update the drug's label.
-
CLINICAL_TRIALS research · 2018-03-22Clinical Trial Update: Second STOP After Pioglitazone Priming in CML Patients [Phase 2]
Phase 2 clinical trial update on pioglitazone priming for patients with chronic myeloid leukemia, outlining a second STOP strategy.
-
CLINICAL_TRIALS trial_result · 2018-03-13Clinical Trial Update: Multicenter Trial Estimating the Persistence of Molecular Remission in Chronic Myeloid Leukaemia in Long Term After Stopping Imatinib [NA]
This completed multicenter trial investigates how long patients with chronic myeloid leukemia stay in molecular remission after stopping ima…
-
CLINICAL_TRIALS trial_result · 2018-02-27Clinical Trial Update: The Study of the Efficacy and the Safety of Flumatinib vs Imatinib as First Line Treatment in Patients With CML [Phase 3]
A Phase 3 trial comparing flumatinib to imatinib as first-line therapy for chronic myeloid leukemia has completed.
-
CLINICAL_TRIALS trial_result · 2018-01-05Clinical Trial Update: A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib [Phase 2]
Phase II pediatric study evaluating dasatinib for newly diagnosed chronic phase chronic myeloid leukemia or Philadelphia chromosome-positive…
-
FDA approval · 2017-12-22FDA Approved: TASIGNA — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for Tasigna (nilotinib) filed by Novartis Pharmaceuticals Corporation, resulting in updated labeling…
-
FDA approval · 2017-12-19FDA Approved: BOSULIF — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
The FDA approved a supplemental application for Bosulif (bosutinib) from Pfizer Laboratories Div Pfizer Inc. This action expands the regulat…
-
FDA approval · 2017-12-18FDA Approved: DROXIA — Supplemental Application (Waylis Therapeutics LLC)
FDA approved a supplemental application for DROXIA (hydroxyurea) submitted by Waylis Therapeutics LLC.